T. Rowe Price Associates
KYNB

T. Rowe Price Associates’s Kyntra Bio KYNB Stock Holding History

T. Rowe Price Associates’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,640
Closed -$61K – 3051
2024
Q4 		$61K Sell
4,640
-1,620
-26% -$15.1K ﹤0.01% 2906
2024
Q3 		$63K Buy
6,260
+2,544
+68% +$38.4K ﹤0.01% 2900
2024
Q2 		$83K Sell
3,716
-974
-21% -$30.1K ﹤0.01% 2780
2024
Q1 		$276K Buy
4,690
+234
+5% +$10.1K ﹤0.01% 2473
2023
Q4 		$99K Buy
4,456
+1,628
+58% +$24.6K ﹤0.01% 2718
2023
Q3 		$62K Buy
2,828
+976
+53% +$38.3K ﹤0.01% 2749
2023
Q2 		$126K Sell
1,852
-30,493
-94% -$12.6M ﹤0.01% 2646
2023
Q1 		$15.1M Sell
32,345
-4,780
-13% -$2.53M ﹤0.01% 986
2022
Q4 		$14.9M Buy
37,125
+35,794
+2,689% +$13.7M ﹤0.01% 986
2022
Q3 		$433K Buy
1,331
+517
+64% +$167K ﹤0.01% 2195
2022
Q2 		$215K Buy
814
+117
+17% +$29.9K ﹤0.01% 2575
2022
Q1 		$209K Buy
697
+168
+32% +$58.6K ﹤0.01% 2696
2021
Q4 		$186K Sell
529
-736
-58% -$229K ﹤0.01% 2776
2021
Q3 		$323K Sell
1,265
-18,594
-94% -$6.59M ﹤0.01% 2552
2021
Q2 		$13.2M Sell
19,859
-56,064
-74% -$32.3M ﹤0.01% 1379
2021
Q1 		$65.9M Sell
75,923
-69,173
-48% -$73.7M 0.01% 901
2020
Q4 		$135M Sell
145,096
-8,939
-6% -$9.4M 0.01% 629
2020
Q3 		$158M Sell
154,035
-10,650
-6% -$11.5M 0.02% 538
2020
Q2 		$167M Buy
164,685
+82,606
+101% +$76.7M 0.02% 515
2020
Q1 		$71.3M Sell
82,079
-11,480
-12% -$11.4M 0.01% 676
2019
Q4 		$100M Sell
93,559
-5,870
-6% -$5.99M 0.01% 666
2019
Q3 		$91.9M Buy
99,429
+269
+0.3% +$295K 0.01% 649
2019
Q2 		$112M Sell
99,160
-2,732
-3% -$2.99M 0.02% 616
2019
Q1 		$138M Buy
101,892
+10,800
+12% +$14.6M 0.02% 556
2018
Q4 		$105M Sell
91,092
-2,591
-3% -$2.91M 0.02% 596
2018
Q3 		$142M Sell
93,683
-762
-0.8% -$1.17M 0.02% 570
2018
Q2 		$148M Buy
94,445
+16,439
+21% +$21.4M 0.02% 556
2018
Q1 		$90.1M Buy
78,006
+13,561
+21% +$17.9M 0.01% 681
2017
Q4 		$76.4M Buy
64,445
+10,325
+19% +$12.9M 0.01% 726
2017
Q3 		$72.8M Buy
54,120
+21,902
+68% +$23.1M 0.01% 727
2017
Q2 		$26M Sell
32,218
-223
-0.7% -$155K ﹤0.01% 1077
2017
Q1 		$20M Sell
32,441
-1,631
-5% -$993K ﹤0.01% 1164
2016
Q4 		$18.2M Sell
34,072
-2,085
-6% -$1.04M ﹤0.01% 1171
2016
Q3 		$18.7M Sell
36,157
-872
-2% -$411K ﹤0.01% 1157
2016
Q2 		$15.2M Sell
37,029
-24
-0.1% -$11K ﹤0.01% 1184
2016
Q1 		$19.7M Sell
37,053
-110
-0.3% -$54.8K ﹤0.01% 1081
2015
Q4 		$28.3M Buy
37,163
+210
+0.6% +$139K 0.01% 977
2015
Q3 		$20.3M Sell
36,953
-408
-1% -$247K ﹤0.01% 1082
2015
Q2 		$21.9M Sell
37,361
-1,736
-4% -$1.01M ﹤0.01% 1104
2015
Q1 		$30.3M Sell
39,097
-52
-0.1% -$40.3K 0.01% 1016
2014
Q4 		$26.4M Buy
+39,149
New +$25.2M 0.01% 1050

Other funds holding KYNB

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates's KYNB Position: Q1 2025 in Review

T. Rowe Price Associates sold out of Kyntra Bio (KYNB) in Q1 2025, closing a stake of 4,640 shares — an estimated $61K sold.

T. Rowe Price Associates first reported a position in KYNB in Q4 2014 and held it in 41 quarters. The position peaked at $167M in Q2 2020. 54 funds tracked by Wall St. Rank hold KYNB as of Q1 2025.

  • T. Rowe Price Associates reported no remaining Kyntra Bio position as of Q1 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 4,640 Kyntra Bio shares in Q1 2025, an estimated $61K.
  • T. Rowe Price Associates first reported a position in Kyntra Bio in Q4 2014 and held it in 41 quarters.
  • T. Rowe Price Associates's Kyntra Bio position peaked at $167M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2025.

Based on T. Rowe Price Associates's 13F filing for Q1 2025, filed 14 May 2025.